Research programme: cyclin M4 targeting siRNA therapeutics - Silence Therapeutics
Alternative Names: Cnnm4 siRNA- Silence TherapeuticsLatest Information Update: 24 Aug 2021
At a glance
- Originator Silence Therapeutics
- Class Amines; Amino sugars; Drug conjugates; Hepatoprotectants; Small interfering RNA
- Mechanism of Action CNNM4 protein inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver disorders; Non-alcoholic steatohepatitis
Most Recent Events
- 23 Jun 2021 Preclinical trials in Liver disorders in Germany (IV)
- 23 Jun 2021 Pharmacodynamics data from a preclinical trial in Liver disorders presented at the International Liver Congress 2021 (ILC-2021)
- 31 Jan 2021 Pharmacodynamics data from a preclinical trial in Non-alcoholic steatohepatitis released by Silence Therapeutics